aTyr Pharma, Inc. cash flow to debt ratio of -515.13% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

aTyr Pharma, Inc.'s free cash flow has increased 10.29% from $-69.18M last year to $-62.06M, signaling increasing performance

aTyr Pharma, Inc.'s debt to equity ratio is 0.23, which means that the company's assets are healthy financed, signaling financial stability.

aTyr Pharma, Inc.'s debt has increased relative to shareholder equity from 0.19 last year to 0.23 today, signaling weakened financials

aTyr Pharma, Inc. has a net cash position, so leverage is healthy.

Interest expense is not separately reported in aTyr Pharma, Inc.'s latest filing, so interest coverage cannot be calculated.

aTyr Pharma, Inc.'s profit margin was -27.24K% last year and is -32.00K% this year, signaling decreasing performance

aTyr Pharma, Inc.'s short-term assets of $80.24M exceed its short-term liabilities of $15.15M

aTyr Pharma, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

aTyr Pharma, Inc.'s return on equity of -95.59%, is lower than 15.00%, indicating bad performance

aTyr Pharma, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

aTyr Pharma, Inc. has insufficient public price history to evaluate earnings stability.

aTyr Pharma, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

aTyr Pharma, Inc. has negative free cash flow, indicating cash burn

aTyr Pharma, Inc.'s yearly earnings has decreased 15.77% since last year from $-64.02M to $-74.12M, signaling decreasing performance

aTyr Pharma, Inc.'s yearly revenue has decreased 19.15% since last year from $235.00K to $190.00K, signaling decreasing performance

ROIC -106.59% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

aTyr Pharma, Inc.'s 3-year revenue CAGR of -73.65% is negative, indicating declining revenue over the past 3 years

aTyr Pharma, Inc. has insufficient public price history to evaluate revenue consistency.

aTyr Pharma, Inc. has insufficient public price history to evaluate ROE consistency.

aTyr Pharma, Inc. has insufficient data to evaluate this check.

aTyr Pharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

aTyr Pharma, Inc. is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

aTyr Pharma, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

aTyr Pharma, Inc. has insufficient data to evaluate this check.

aTyr Pharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

aTyr Pharma, Inc. has a price-to-book ratio of 0.62x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

aTyr Pharma, Inc. has a price-to-sales ratio of 160.53x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue